Ardelyx Inc.
34175 Ardenwood Boulevard
Suite 100
Fremont
California
94555
United States
Tel: 510-745-1700
Website: http://www.ardelyx.com/
263 articles about Ardelyx Inc.
-
Ardelyx to Report First Quarter 2024 Financial Results on May 2, 2024Conference call scheduled for 4:30 p.m. Eastern Time
4/18/2024
Ardelyx, Inc today announced it will hold a conference call on Thursday, May 2, 2024, at 4:30 p.m. Eastern Time to discuss financial results and provide a business update from the first quarter of 2024.
-
Ardelyx Appoints Veteran BioPharma Executive, Mike Kelliher, as Executive Vice President, Corporate Development and Strategy
3/25/2024
Ardelyx, Inc. today announced the appointment of Mike Kelliher to the position of Executive Vice President, Corporate Development and Strategy.
-
Ardelyx, Inc. Reports Employment Inducement Grants - March 12, 2024
3/12/2024
Ardelyx, Inc. announced that on March 9, 2024, the compensation committee of the company’s board of directors granted nine new non-executive employees options to purchase an aggregate of 207,038 shares of the company’s common stock, and granted twelve new non-executive employees an aggregate of 157,450 Restricted Stock Units.
-
Ardelyx to Participate at the Cowen 44th Annual Health Care Conference
2/27/2024
Ardelyx, Inc. (Nasdaq: ARDX) today announced that Susan Rodriguez, chief commercial officer of Ardelyx, will participate in a Cardiorenal panel discussion at the Cowen 44th Annual Health Care Conference on Tuesday, March 5, 2024 at 10:30 A.M. Eastern Time in Boston, MA.
-
Ardelyx Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update
2/22/2024
Ardelyx, Inc. (Nasdaq: ARDX) today reported financial results for the fourth quarter and full year ended December 31, 2023 and provided a business update.
-
Ardelyx to Report Fourth Quarter and Full Year 2023 Financial Results on February 22, 2024Conference call scheduled for 4:30 p.m. Eastern Time
2/1/2024
Ardelyx, Inc. today announced it will hold a conference call on Thursday, February 22, 2024, at 4:30 p.m. Eastern Time to discuss fourth quarter and full year 2023 financial results and provide a business update.
-
Ardelyx, Inc. Reports Employment Inducement Grants - Jan 12, 2024
1/12/2024
Ardelyx, Inc. announced that on January 10, 2024, the compensation committee of the company’s board of directors granted two new non-executive employees options to purchase an aggregate of 23,580 shares of the company’s common stock, and granted three new non-executive employees an aggregate of 33,300 Restricted Stock Units.
-
Ardelyx Provides Update on Growing Commercial Momentum and 2024 Strategic Priorities
1/8/2024
Ardelyx, Inc. provided an update on the company’s progress in 2023 and initial expectations for 2024.
-
Ardelyx to Provide Company Update on IBSRELA® and Host a KOL Discussion on the IBS-C Landscape on Monday, January 8
1/3/2024
Ardelyx, Inc. today announced it will host a live event and webcast on Monday, January 8, 2024, at 7:00 p.m. ET / 4:00 p.m. PT.
-
Ardelyx, Inc. Reports Employment Inducement Grants - December 20, 2023
12/20/2023
Ardelyx, Inc. announced that on December 18, 2023, the compensation committee of the company’s board of directors granted sixteen new non-executive employees options to purchase an aggregate of 257,119 shares of the company’s common stock, and granted eighteen new non-executive employees an aggregate of 201,981 Restricted Stock Units.
-
Ardelyx, Inc. Reports Employment Inducement Grants - November 21, 2023
11/21/2023
Ardelyx, Inc. announced that on November 20, 2023, the compensation committee of the company’s board of directors granted fourteen new non-executive employees options to purchase an aggregate of 221,805 shares of the company’s common stock, and granted sixteen new non-executive employees an aggregate of 182,068 Restricted Stock Units.
-
Ardelyx to Participate at the Piper Sandler 35th Annual Healthcare Conference
11/21/2023
Ardelyx, Inc. today announced that Ardelyx management will participate in a fireside chat at the Piper Sandler 35th Annual Healthcare Conference on Wednesday, November 29, 2023, at 2:30 p.m. E.T. in New York City.
-
XPHOZAH® (tenapanor) Granted Orphan Drug Designation by U.S. FDA for the Treatment of Pediatric Hyperphosphatemia
11/15/2023
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today announced that the U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation to XPHOZAH® (tenapanor) for the treatment of pediatric hyperphosphatemia.
-
Ardelyx Announces Departure of Board Member - November 13, 2023
11/13/2023
Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, announced that Geoffrey Block, MD, is stepping down from the Board of Directors after nearly five years of service.
-
Ardelyx to Participate at the 2023 Jefferies London Healthcare Conference
11/10/2023
Ardelyx, Inc. announced that Ardelyx management will participate in a fireside chat at the Jefferies London Healthcare Conference on Thursday, November 16, 2023, at 8:30 a.m. GMT in London, UK.
-
Ardelyx Announces XPHOZAH® (tenapanor) Now Available in the United States
11/6/2023
Ardelyx, Inc. announced XPHOZAH is now available for shipment to partner pharmacies.
-
Ardelyx Shares Positive Data from Studies of XPHOZAH® (tenapanor), a First-in-Class Phosphate Absorption Inhibitor, at ASN Kidney Week 2023
11/3/2023
Ardelyx, Inc. (Nasdaq: ARDX), a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, today shared positive data on the use of XPHOZAH® (tenapanor) in poster presentations at the American Society of Nephrology (ASN) Kidney Week 2023 meeting.
-
Ardelyx Reports Third Quarter 2023 Financial Results and Updates 2023 U.S. IBSRELA® Net Sales Revenue Guidance
10/31/2023
Ardelyx, Inc., a biopharmaceutical company founded with a mission to discover, develop and commercialize innovative, first-in-class medicines that meet significant unmet medical needs, reported financial results for the third quarter ended September 30, 2023 and provided a business update.
-
Ardelyx, Inc. Reports Employment Inducement Grants - October 30, 2023
10/30/2023
Ardelyx, Inc. announced between October 11, 2023 and October 29, 2023 the compensation committee of the company’s board of directors granted forty-seven new non-executive employees options to purchase an aggregate of 635,024 shares of the company’s common stock, and granted fifty-one new non-executive employees an aggregate of 591,900 Restricted Stock Units.
-
Ardelyx Shares Positive Data on Symptom Response During Treatment With IBSRELA® (tenapanor) for IBS-C and hosts IBS-C Product Theater at ACG 2023
10/23/2023
Ardelyx, Inc. announced that they will share positive data on IBSRELA ® (tenapanor) via an oral presentation and two posters at the American College of Gastroenterology (ACG) annual meeting, being held October 20 to 25 in Vancouver, Canada.